These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 15332287

  • 1. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Satoh J, Kobayashi M, Ikeda K, Miyakawa Y, Kumada H.
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [Abstract] [Full Text] [Related]

  • 2. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W, Shirakawa H, Kawakami Y, Kimura S, Kamiyasu M, Tazuma S, Nakanishi T, Chayama K.
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [Abstract] [Full Text] [Related]

  • 3. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H.
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [Abstract] [Full Text] [Related]

  • 4. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Guptan RC, Thakur V, Hasnain SE, Sarin SK.
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [Abstract] [Full Text] [Related]

  • 5. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF, Yang DH, Shen YH, Xie YJ, Zhao NF.
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [Abstract] [Full Text] [Related]

  • 6. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [Abstract] [Full Text] [Related]

  • 7. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN, Chauhan R, Das BC, Sarin SK.
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [Abstract] [Full Text] [Related]

  • 8. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Arslan U, Ural O, Findik D.
    Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
    [Abstract] [Full Text] [Related]

  • 9. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
    Pan XP, Wo JE, Chen Z, Chen F, Liang WF, Liu KZ.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
    [Abstract] [Full Text] [Related]

  • 10. Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy.
    Akuta N, Suzuki F, Kobayashi M, Matsuda M, Sato J, Takagi K, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2003 Dec; 71(4):504-10. PubMed ID: 14556262
    [Abstract] [Full Text] [Related]

  • 11. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.
    Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM.
    Int J Infect Dis; 2008 Jan; 12(1):83-7. PubMed ID: 17698384
    [Abstract] [Full Text] [Related]

  • 12. [Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients].
    Shin YM, Heo J, Kim GH, Kang DH, Song GA, Cho M, Yang US, Kim CM, Park HK, Jang HJ.
    Taehan Kan Hakhoe Chi; 2003 Mar; 9(1):1-9. PubMed ID: 12657823
    [Abstract] [Full Text] [Related]

  • 13. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ.
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C, Ajana F, Canva V, Mouton Y, Yazdanpanah Y, Wattré P, Bocket L.
    Ann Biol Clin (Paris); 2002 Nov; 60(5):581-8. PubMed ID: 12368144
    [Abstract] [Full Text] [Related]

  • 15. [Dynamic variations of hepatitis B virus polymerase gene in lamivudine-treated hepatitis B patients].
    Feng B, Wei L, Chen M, Han FZ, Wang LP.
    Zhonghua Gan Zang Bing Za Zhi; 2006 May; 14(5):327-30. PubMed ID: 16732904
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
    Deng H, Lv Y, Fu J.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
    [Abstract] [Full Text] [Related]

  • 17. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
    Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi M, Andreone P.
    Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
    [Abstract] [Full Text] [Related]

  • 18. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
    Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH.
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
    [Abstract] [Full Text] [Related]

  • 19. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM.
    Antivir Ther; 2006 Dec; 11(4):447-55. PubMed ID: 16856618
    [Abstract] [Full Text] [Related]

  • 20. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF.
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.